Sanara MedTech
Medical technology company focused on development, manufacture and distribution of surgical, wound care and dermatology products and related services in North America. Offers biologic and allograft materials, hydrolyzed collagen products, antimicrobial wound-care formulations, and remote wound/dermatology consultation services. Operates a state-licensed, FDA-registered tissue bank and advances products from preclinical testing through regulatory clearance and commercial launch.
Industries
Nr. of Employees
medium (51-250)
Sanara MedTech
Fort Worth, Texas, United States
Patents
Products
CellerateRX Surgical Powder
Type I bovine hydrolyzed collagen formulation intended for surgical wound applications.
No-rinse surgical irrigation solution
No-rinse irrigation and cleansing solution formulated with antimicrobial preservative components for mechanical cleansing and reduction of microorganisms from surgical wounds.
Fortify TRG Tissue Repair Graft
Porcine small intestinal submucosa extracellular matrix intended for soft tissue reinforcement and implantation.
Fortify Flowable extracellular matrix
Micronized porcine small intestinal submucosa extracellular matrix provided as a flowable material for surgical wounds.
Amniotic membrane allograft
Multilayer amniotic membrane for use as a soft tissue barrier and wound covering.
Advanced viable bone matrix
Cellular bone allograft containing viable bone-derived progenitor cells preserved with a DMSO-free cryoprotectant for bone grafting applications.
CellerateRX Surgical Powder
Type I bovine hydrolyzed collagen formulation intended for surgical wound applications.
No-rinse surgical irrigation solution
No-rinse irrigation and cleansing solution formulated with antimicrobial preservative components for mechanical cleansing and reduction of microorganisms from surgical wounds.
Fortify TRG Tissue Repair Graft
Porcine small intestinal submucosa extracellular matrix intended for soft tissue reinforcement and implantation.
Fortify Flowable extracellular matrix
Micronized porcine small intestinal submucosa extracellular matrix provided as a flowable material for surgical wounds.
Amniotic membrane allograft
Multilayer amniotic membrane for use as a soft tissue barrier and wound covering.
Advanced viable bone matrix
Cellular bone allograft containing viable bone-derived progenitor cells preserved with a DMSO-free cryoprotectant for bone grafting applications.
Services
Telemedicine consultations for wound care and dermatology using licensed clinician networks and integrated telehealth platforms.
State-licensed and FDA-registered tissue bank services for storage, handling and distribution of allograft tissue products.
Telemedicine consultations for wound care and dermatology using licensed clinician networks and integrated telehealth platforms.
State-licensed and FDA-registered tissue bank services for storage, handling and distribution of allograft tissue products.
Expertise Areas
- Wound care product development
- Surgical biologics and allografts
- Orthobiologics and bone graft materials
- Antimicrobial formulation and biofilm disruption
Key Technologies
- Allograft processing and sterilization methods
- Hydrolyzed collagen production
- Extracellular matrix scaffold technologies
- Cryopreservation of viable cellular allografts (DMSO-free cryoprotectants)
News & Updates
Announcement of acquisition of proprietary assets related to hydrolyzed collagen products including patents, trademarks and 510(k) cleared products; transaction expected to provide control of manufacturing and IP for collagen wound care products.
Announcement of acquisition closing for a biologics company operating a licensed tissue bank, expanding tissue bank and allograft distribution capabilities.
Quarterly update describing revenue growth, expansion of virtual wound and skin care strategy, investments in telehealth technologies and product launches including antimicrobial wound products.
Announcement of acquisition of proprietary assets related to hydrolyzed collagen products including patents, trademarks and 510(k) cleared products; transaction expected to provide control of manufacturing and IP for collagen wound care products.
Announcement of acquisition closing for a biologics company operating a licensed tissue bank, expanding tissue bank and allograft distribution capabilities.
Quarterly update describing revenue growth, expansion of virtual wound and skin care strategy, investments in telehealth technologies and product launches including antimicrobial wound products.